Advertiser / Brand
Galderma vs STADA
Structured technology and market comparison · 2026
Direct Feature Comparison
Galderma · vs · STADAGlobal dermatology company spanning therapeutics, aesthetics and skincare.
Pharmaceutical group selling generics, specialty medicines and consumer healthcare.
Analyze all overlapping signals and tech stacks for Galderma and STADA
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Galderma and STADA?
When comparing Galderma and STADA, both platforms operate within the Advertiser / Brand ecosystem. Galderma is positioned as Global dermatology company spanning therapeutics, aesthetics and skincare, whereas STADA focuses on Pharmaceutical group selling generics, specialty medicines and consumer healthcare. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Galderma and STADA?
When evaluating Galderma and STADA, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Galderma and STADA compare?
Galderma is headquartered in Switzerland (founded in 1981) with >5,000 employees. STADA is based in Germany (founding year unrecorded) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Galderma vs STADA
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Galderma
Recent Signals
- ·Galderma
Fall Clinical 2026: Galderma presents new three-year Nemluvio® data showing deep and lasting skin lesion and itch responses in patients with atopic dermatitis aged 12 and older
Galderma's latest press release announces new three-year data for Nemluvio® in atopic dermatitis, presented at Fall Clinical 2026.
- ·Galderma
EADV 2026: Galderma’s new data show sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis
Galderma announced new three-year data from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) provides sustained improvements in moderate-to-severe atopic dermatitis for up to 152 weeks. At Week 152, up to 91% of patients achieved EASI-75, up to 67% achieved near-complete skin clearance, and approximately 90% reported clinically meaningful improvements in itch and quality of life. The findings were presented at the EADV 2026 Congress in Vienna, Austria, which runs September 30 to October 3, 2026. Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis in more than 40 countries.
- Galderma published the press release on September 30, 2026, announcing new three-year ARCADIA long-term extension data for Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis.
- At Week 152, up to 91% of patients achieved EASI-75, up to 75% achieved EASI-90, up to 67% achieved IGA 0/1, up to 88% achieved clinically meaningful itch relief, and up to 92% achieved clinically meaningful quality-of-life improvement.
- The findings were presented at the EADV 2026 Congress in Vienna, Austria, with the oral presentation scheduled for Thursday, October 1, 2026.
- ·Galderma
Galderma begins trading in the Swiss Market Index, joining Switzerland's leading blue chip companies
Galderma has been added to the Swiss Market Index (SMI), marking its inclusion among Switzerland's leading blue-chip companies. This is a major corporate milestone for the company.
STADA
Recent Signals
No recent market signals documented for STADA in the current tracking window.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Galderma and STADA share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks